9931 related articles for article (PubMed ID: 1912517)
21. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?
Altomonte M; Fonsatti E; Visintin A; Maio M
Oncogene; 2003 Sep; 22(42):6564-9. PubMed ID: 14528281
[TBL] [Abstract][Full Text] [Related]
22. Expression of the heat shock cognate protein HSP73 correlates with tumour thickness of primary melanomas and is enhanced in melanoma metastases.
Deichmann M; Polychronidis M; Benner A; Kleist C; Thome M; Kahle B; Helmke BM
Int J Oncol; 2004 Aug; 25(2):259-68. PubMed ID: 15254721
[TBL] [Abstract][Full Text] [Related]
23. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
[TBL] [Abstract][Full Text] [Related]
24. Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer.
Concha A; Esteban F; Cabrera T; Ruiz-Cabello F; Garrido F
Semin Cancer Biol; 1991 Feb; 2(1):47-54. PubMed ID: 1912518
[TBL] [Abstract][Full Text] [Related]
25. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma.
Blom DJ; Luyten GP; Mooy C; Kerkvliet S; Zwinderman AH; Jager MJ
Invest Ophthalmol Vis Sci; 1997 Aug; 38(9):1865-72. PubMed ID: 9286277
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma.
Natali P; Bigotti A; Cavaliere R; Liao SK; Taniguchi M; Matsui M; Ferrone S
Cancer Res; 1985 Jun; 45(6):2883-9. PubMed ID: 3157450
[TBL] [Abstract][Full Text] [Related]
27. Association of HLA class I and class II antigen expression and mortality in uveal melanoma.
Ericsson C; Seregard S; Bartolazzi A; Levitskaya E; Ferrone S; Kiessling R; Larsson O
Invest Ophthalmol Vis Sci; 2001 Sep; 42(10):2153-6. PubMed ID: 11527924
[TBL] [Abstract][Full Text] [Related]
28. Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients.
Anichini A; Mortarini R; Nonaka D; Molla A; Vegetti C; Montaldi E; Wang X; Ferrone S
Cancer Res; 2006 Jun; 66(12):6405-11. PubMed ID: 16778219
[TBL] [Abstract][Full Text] [Related]
29. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas.
Cordon-Cardo C; Fuks Z; Drobnjak M; Moreno C; Eisenbach L; Feldman M
Cancer Res; 1991 Dec; 51(23 Pt 1):6372-80. PubMed ID: 1933900
[TBL] [Abstract][Full Text] [Related]
30. HLA-DR synthesis induction and expression in HLA-DR-negative carcinoma cell lines of diverse origins by interferon-gamma but not by interferon-beta.
Shaw AR; Chan JK; Reid S; Seehafer J
J Natl Cancer Inst; 1985 Jun; 74(6):1261-8. PubMed ID: 3923246
[TBL] [Abstract][Full Text] [Related]
31. High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Rodriguez T; Méndez R; Roberts CH; Ruiz-Cabello F; Dodi IA; López Nevot MA; Paco L; Maleno I; Marsh SG; Pawelec G; Garrido F
Cancer Immunol Immunother; 2005 Feb; 54(2):141-8. PubMed ID: 15592718
[TBL] [Abstract][Full Text] [Related]
32. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma.
Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP
Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497
[TBL] [Abstract][Full Text] [Related]
33. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.
Rodríguez T; Méndez R; Del Campo A; Jiménez P; Aptsiauri N; Garrido F; Ruiz-Cabello F
BMC Cancer; 2007 Feb; 7():34. PubMed ID: 17319941
[TBL] [Abstract][Full Text] [Related]
34. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma.
Gastl G; Ebert T; Finstad CL; Sheinfeld J; Gomahr A; Aulitzky W; Bander NH
J Urol; 1996 Jan; 155(1):361-7. PubMed ID: 7490887
[TBL] [Abstract][Full Text] [Related]
35. HLA expression in choroidal melanomas: correlation with clinicopathological features.
Krishnakumar S; Abhyankar D; Lakshmi SA; Pushparaj V; Shanmugam MP; Biswas J
Curr Eye Res; 2004 Jun; 28(6):409-16. PubMed ID: 15512948
[TBL] [Abstract][Full Text] [Related]
36. Immunohistological evaluation of MHC class I and II antigen expression on nevi and melanoma: relation to biology of melanoma.
D'Alessandro G; Zardawi I; Grace J; McCarthy WH; Hersey P
Pathology; 1987 Oct; 19(4):339-46. PubMed ID: 3328139
[TBL] [Abstract][Full Text] [Related]
37. Phenotypic dynamics of tumor progression in human malignant melanoma.
Bröcker EB; Suter L; Brüggen J; Ruiter DJ; Macher E; Sorg C
Int J Cancer; 1985 Jul; 36(1):29-35. PubMed ID: 3860479
[TBL] [Abstract][Full Text] [Related]
38. Ki67 antigen expression correlates with tumor progression and HLA-DR antigen expression in melanocytic lesions.
Moretti S; Massobrio R; Brogelli L; Novelli M; Giannotti B; Bernengo MG
J Invest Dermatol; 1990 Sep; 95(3):320-4. PubMed ID: 1696603
[TBL] [Abstract][Full Text] [Related]
39. Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes.
Holzmann B; Bröcker EB; Lehmann JM; Ruiter DJ; Sorg C; Riethmüller G; Johnson JP
Int J Cancer; 1987 Apr; 39(4):466-71. PubMed ID: 3104215
[TBL] [Abstract][Full Text] [Related]
40. HLA expression in uveal melanoma: there is no rule without some exception.
Jager MJ; Hurks HM; Levitskaya J; Kiessling R
Hum Immunol; 2002 Jun; 63(6):444-51. PubMed ID: 12039519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
